Currently, a novel FASN inhibitor, TVB-2640, is being tested in several Phase I-II oncology clinical trials (104, 105); thus, providing the opportunity to test inhibition of de novo lipogenesis as a preventive therapeutic approach for CRC. The gene discussed is FASN; the disease is colorectal carcinoma.